These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 24521854)

  • 1. Rilpivirine exposure in plasma and sanctuary site compartments after switching from nevirapine-containing combined antiretroviral therapy.
    Mora-Peris B; Watson V; Vera JH; Weston R; Waldman AD; Kaye S; Khoo S; Mackie NE; Back D; Winston A
    J Antimicrob Chemother; 2014 Jun; 69(6):1642-7. PubMed ID: 24521854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switching from tenofovir/emtricitabine and nevirapine to a tenofovir/emtricitabine/rilpivirine single-tablet regimen in virologically suppressed, HIV-1-infected subjects.
    Allavena C; Dailly E; Reliquet V; Bonnet B; Pineau S; André-Garnier E; Boutoille D; Bouquié R; Raveleau A; Bouchez S; Billaud E; Raffi F
    J Antimicrob Chemother; 2014 Oct; 69(10):2804-8. PubMed ID: 24907142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy, pharmacokinetics, and safety of a nevirapine to rilpivirine switch in virologically suppressed HIV-1-infected patients.
    Rokx C; Blonk M; Verbon A; Burger D; Rijnders BJ
    J Acquir Immune Defic Syndr; 2015 Jan; 68(1):36-9. PubMed ID: 25247434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Archived HIV-1 DNA resistance mutations to rilpivirine and etravirine in successfully treated HIV-1-infected individuals pre-exposed to efavirenz or nevirapine.
    Gallien S; Charreau I; Nere ML; Mahjoub N; Simon F; de Castro N; Aboulker JP; Molina JM; Delaugerre C
    J Antimicrob Chemother; 2015 Feb; 70(2):562-5. PubMed ID: 25344807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens.
    Mills AM; Cohen C; Dejesus E; Brinson C; Williams S; Yale KL; Ramanathan S; Wang MH; White K; Chuck SK; Cheng AK
    HIV Clin Trials; 2013; 14(5):216-23. PubMed ID: 24144898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of food on rilpivirine/emtricitabine/tenofovir disoproxil fumarate, an antiretroviral single-tablet regimen for the treatment of HIV infection.
    Custodio JM; Yin X; Hepner M; Ling KH; Cheng A; Kearney BP; Ramanathan S
    J Clin Pharmacol; 2014 Apr; 54(4):378-85. PubMed ID: 24142299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concentration-response model of rilpivirine in a cohort of HIV-1-infected naive and pre-treated patients.
    Néant N; Solas C; Bouazza N; Lê MP; Yazdanpanah Y; Dhiver C; Bregigeon S; Mokhtari S; Peytavin G; Tamalet C; Descamps D; Lacarelle B; Gattacceca F
    J Antimicrob Chemother; 2019 Jul; 74(7):1992-2002. PubMed ID: 31225609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Penetration and antiviral efficacy of total and unbound maraviroc, raltegravir and rilpivirine in both female and male genital fluids from HIV-positive patients receiving regimens containing these antiretrovirals.
    Lê MP; Belarbi L; Chaix ML; Dulioust E; Mahjoub N; Salmon D; Viard JP; Duvivier C; Peytavin G; Launay O; Ghosn J
    J Antimicrob Chemother; 2017 Nov; 72(11):3167-3171. PubMed ID: 28961979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switching to emtricitabine, tenofovir and rilpivirine as single tablet regimen in virologically suppressed HIV-1-infected patients: a cohort study.
    Gantner P; Reinhart S; Partisani M; Baldeyrou M; Batard ML; Bernard-Henry C; Cheneau C; de Mautort E; Priester M; Fafi-Kremer S; Muret P; Rey D
    HIV Med; 2015 Feb; 16(2):132-6. PubMed ID: 25124291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study.
    Manosuthi W; Sungkanuparph S; Tantanathip P; Lueangniyomkul A; Mankatitham W; Prasithsirskul W; Burapatarawong S; Thongyen S; Likanonsakul S; Thawornwa U; Prommool V; Ruxrungtham K;
    Clin Infect Dis; 2009 Jun; 48(12):1752-9. PubMed ID: 19438397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elvitegravir concentrations in seminal plasma in HIV-1-infected men.
    Imaz A; Niubó J; Kashuba AD; Ferrer E; Sykes C; Rozas N; Acerete L; Vila A; Podzamczer D
    HIV Med; 2017 Mar; 18(3):225-230. PubMed ID: 27477062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nevirapine, sodium concentration and HIV-1 RNA in breast milk and plasma among HIV-infected women receiving short-course antiretroviral prophylaxis.
    Salado-Rasmussen K; Theilgaard ZP; Chiduo MG; Bygbjerg IC; Gerstoft J; Lüneborg-Nielsen M; Lemnge M; Katzenstein TL
    PLoS One; 2015; 10(3):e0121111. PubMed ID: 25812161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short communication: Lipids and cardiovascular risk after switching HIV-1 patients on nevirapine and emtricitabine/tenofovir-DF to rilpivirine/emtricitabine/tenofovir-DF.
    Rokx C; Verbon A; Rijnders BJ
    AIDS Res Hum Retroviruses; 2015 Apr; 31(4):363-7. PubMed ID: 25625211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics of Rilpivirine in HIV-1-infected patients treated with the single-tablet regimen rilpivirine/tenofovir/emtricitabine.
    Néant N; Gattacceca F; Lê MP; Yazdanpanah Y; Dhiver C; Bregigeon S; Mokhtari S; Peytavin G; Tamalet C; Descamps D; Lacarelle B; Solas C
    Eur J Clin Pharmacol; 2018 Apr; 74(4):473-481. PubMed ID: 29374296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concentrations of nevirapine, lamivudine and stavudine in semen of HIV-1-infected men.
    Taylor S; van Heeswijk RP; Hoetelmans RM; Workman J; Drake SM; White DJ; Pillay D
    AIDS; 2000 Sep; 14(13):1979-84. PubMed ID: 10997403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-1 CNS in vitro infectivity models based on clinical CSF samples.
    Mora-Peris B; Winston A; Garvey L; Else LJ; Shattock RJ; Herrera C
    J Antimicrob Chemother; 2016 Jan; 71(1):235-43. PubMed ID: 26472771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials.
    Cohen CJ; Molina JM; Cahn P; Clotet B; Fourie J; Grinsztejn B; Wu H; Johnson MA; Saag M; Supparatpinyo K; Crauwels H; Lefebvre E; Rimsky LT; Vanveggel S; Williams P; Boven K; ;
    J Acquir Immune Defic Syndr; 2012 May; 60(1):33-42. PubMed ID: 22343174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.
    Molina JM; Cahn P; Grinsztejn B; Lazzarin A; Mills A; Saag M; Supparatpinyo K; Walmsley S; Crauwels H; Rimsky LT; Vanveggel S; Boven K;
    Lancet; 2011 Jul; 378(9787):238-46. PubMed ID: 21763936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Twenty-four-week efficacy and safety of switching virologically suppressed HIV-1-infected patients from nevirapine immediate release 200 mg twice daily to nevirapine extended release 400 mg once daily (TRANxITION).
    Arasteh K; Ward D; Plettenberg A; Livrozet JM; Orkin C; Cordes C; Guo J; Wang E; Yong CL; Robinson P; Quinson A
    HIV Med; 2012 Apr; 13(4):236-44. PubMed ID: 22136068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Viral Kinetics in Semen With Different Antiretroviral Families in Treatment-Naive Human Immunodeficiency Virus-Infected Patients: A Randomized Trial.
    Gutierrez-Valencia A; Benmarzouk-Hidalgo OJ; Rivas-Jeremías I; Espinosa N; Trujillo-Rodríguez M; Fernandez-Magdaleno T; Viciana P; López-Cortés LF
    Clin Infect Dis; 2017 Aug; 65(4):551-556. PubMed ID: 28449051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.